Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01

Blood

Volumn 107, Issue 11, 2006, Pages 4508-4513

  Loh, Mignon L ^a   Goldwasser, Meredith A ^b   Silverman, Lewis B ^b   Poon, Wing Man ^b   Vattikuti, Shashaank ^b   Cardoso, Angelo ^b   Neuberg, Donna S ^b   Shannon, Kevin M ^b   Sallan, Stephen E ^b   Gilliland, D Gary ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; BONE MARROW; CANCER CENTER; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE REARRANGEMENT; GENETIC ANALYSIS; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

EID: 33744465219     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3451     Document Type: Article

References (32)

1. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
2. Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 1995;86:4263-4269.
3. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
4. Golub TR, Barker GF, Stegmaier K, Gilliland DG. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 1997;220:67-79.
5. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 1997;16:4374-4383.
6. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995;92:4917-4921.
7. Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995;85:3662-3670.
8. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol. 2001;2:597-607.
9. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
10. Loh ML, Rubnitz JE. TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol. 2002;9:345-352.
11. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
12. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster Study Group. Blood. 1998;91:1716-1722.
13. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
14. Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113:103-114.
15. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
16. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
17. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
18. Takahashi Y, Horibe K, Kiyoi H, et al. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:190-195.
19. Krishna Narla R, Navara C, Sarquis M, Uckun FM. Chemosensitivity of tel-aml1 fusion transcript-positive acute lymphoblastic leukemia cells. Leuk Lymphoma. 2001;41:615-623.
20. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094-1099.
21. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 2003;101:2743-2747.
22. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43:5601-5607.
23. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
24. Whitehead VM, Vuchich MJ, Cooley LD, et al. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Leuk Lymphoma. 1998;31:507-519.
25. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99:2734-2739.
26. Silverman LB, Levy DE, Dalton VK, Lipshultz SE, Gerber RD, Sallan SE. Outcome of Dana-Farber Cancer Institute ALL Consortium protocol 95-01 for children with newly diagnosed acute lymphoblastic leukemia. Presented at: 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, CA.
27. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499-1503.
28. Raynaud S, Cave H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood. 1996;87:2891-2899.
29. Loncarevic IF, Roitzheim B, Ritterbach J, et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer. 1999;24:272-277.
30. Seeger K, Stackelberg AV, Taube T, et al. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J Clin Oncol. 2001;19:3188-3193.
31. Ford AM, Fasching K, Panzer-Grumayer ER, Koenig M, Haas OA, Greaves MF. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood. 2001;98:558-564.
32. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004;10:5355-5360.